Clinical Trials Logo

Solid Malignancies clinical trials

View clinical trials related to Solid Malignancies.

Filter by:

NCT ID: NCT00695370 Terminated - Solid Malignancies Clinical Trials

Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

Start date: January 2006
Phase: Phase 2
Study type: Interventional

Hypothesis: pegfilgrastim at 300 µg/kg in hematological steady state provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study. Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 2 blood volume processed)

NCT ID: NCT00676299 Completed - Pharmacokinetics Clinical Trials

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess JNJ-26483327 (a drug in development for cancer) for the safety of the drug in patients with advanced solid tumors that have not responded or are no longer responding to available therapies. The absorption, breakdown and elimination of the drug will also be studied.

NCT ID: NCT00162136 Completed - Solid Malignancies Clinical Trials

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

Start date: September 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.

NCT ID: NCT00090727 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The purposes of this study are to determine: - the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle - the side effects of AQ4N when given on the above schedule - how much AQ4N is in the blood and urine at specific times after administration and how the body get rids of AQ4N - if AQ4N helps treat cancer

NCT ID: NCT00033202 Completed - Solid Malignancies Clinical Trials

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor

Start date: March 2002
Phase: Phase 1
Study type: Interventional

Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule, rather than by intravenous injection.